Subacute Thyroiditis: Causes, Phases, Diagnosis, and Treatment

What Is Subacute Thyroiditis?

Subacute thyroiditis is a painful, inflammatory condition of the thyroid gland that arises most often in the weeks following an upper respiratory viral infection. The gland becomes tender, swollen, and dysfunctional in a predictable sequence. Because the inflammation is self-limiting, the majority of patients require only symptomatic pain control rather than definitive hormonal therapy.

The condition goes by several names, including de Quervain thyroiditis, granulomatous thyroiditis, and giant-cell thyroiditis, each reflecting a different aspect of its pathology or history. Clinically, the most useful detail is its four-phase hormonal pattern, which separates it clearly from chronic autoimmune conditions such as Hashimoto's thyroiditis or the persistent hyperthyroidism seen in Graves' disease.

Epidemiologically, the condition is far more common in women. Studies in the American Thyroid Association literature place the female-to-male ratio at approximately 4:1, with peak incidence between ages 30 and 50 [1]. A seasonal clustering in summer and autumn, coinciding with enteroviral peaks, has been documented in multiple cohort analyses [2].

What Causes Subacute Thyroiditis?

Viral infection is the most consistently identified trigger, though the precise mechanism involves both direct viral invasion of follicular cells and an HLA-mediated immune response. A genetic predisposition is well established.

HLA-B35 is present in 70 to 80 percent of patients with subacute thyroiditis compared with roughly 30 percent of the general population, according to data published in the Journal of Clinical Endocrinology and Metabolism [3]. This association is stronger than almost any other HLA-disease link in thyroidology and explains why certain individuals repeatedly develop the condition after viral illnesses while their household contacts do not.

Viruses implicated across case series include mumps, Coxsackievirus, Echovirus, adenovirus, influenza, and, more recently, SARS-CoV-2. A 2021 systematic review in Frontiers in Endocrinology identified subacute thyroiditis as a recognized post-COVID-19 complication, with cases appearing two to six weeks after acute SARS-CoV-2 infection [4]. The inflammation is not purely autoimmune; TPO antibodies and thyroglobulin antibodies are typically absent or transiently low, distinguishing this condition from Hashimoto's thyroiditis [1].

The Four Hormonal Phases

Understanding the four phases is the central clinical requirement for managing subacute thyroiditis correctly. Each phase produces a different thyroid function picture, and treatment decisions hinge on which phase the patient occupies.

Phase 1: Thyrotoxic phase (weeks 1 to 6). Inflammation disrupts follicular cells, releasing preformed T3 and T4 into the bloodstream. TSH drops below 0.1 mIU/L. Free T4 rises above the normal range (typically >1.8 ng/dL). Patients experience palpitations, heat intolerance, weight loss, and anxiety alongside severe anterior neck pain that often radiates to the jaw or ear. ESR is characteristically very high, frequently exceeding 50 mm/hr [5].

Phase 2: Euthyroid phase (weeks 4 to 8). Stored hormone is exhausted. TSH normalizes transiently. Symptoms improve, and the neck becomes less tender. This phase may be brief and is sometimes missed clinically.

Phase 3: Hypothyroid phase (weeks 4 to 16). The damaged follicular cells can no longer synthesize adequate hormone. TSH rises, free T4 falls below the lower limit of normal (typically <0.8 ng/dL), and patients develop fatigue, cold intolerance, and constipation. This phase resolves spontaneously in 85 to 95 percent of patients as follicular cells regenerate [1].

Phase 4: Recovery phase. TSH and free T4 normalize. The gland regains full secretory capacity. Approximately 5 to 15 percent of patients fail to recover and require long-term levothyroxine therapy [6].

A practical monitoring schedule based on this phase structure: check TSH and free T4 at diagnosis, then at four weeks, eight weeks, and twelve weeks. If TSH remains elevated and free T4 is low at the twelve-week mark, begin levothyroxine at 1.6 mcg/kg/day and recheck in six to eight weeks.

How Subacute Thyroiditis Is Diagnosed

Diagnosis rests on the combination of a painful thyroid gland, elevated ESR, suppressed TSH with elevated free T4 in the early phase, and low radioactive iodine uptake (RAIU). A 24-hour RAIU below 2 percent in the setting of elevated thyroid hormones is essentially diagnostic and directly excludes Graves' disease, which shows RAIU above 35 percent [7].

The American Thyroid Association's clinical practice guidelines specify that RAIU is the single most useful test for differentiating destructive thyroiditis from hyperthyroidism caused by increased hormone synthesis [7]. A thyroid ultrasound typically reveals diffuse or focal hypoechogenicity without nodularity, but ultrasound alone is insufficient for diagnosis. Fine-needle aspiration biopsy is rarely needed but, when performed, shows giant multinucleated cells and granuloma formation, which is the histological signature of the condition [8].

Key lab benchmarks to document at diagnosis:

• TSH: suppressed, typically <0.1 mIU/L in phase 1
• Free T4: elevated, often 1.8 to 4.0 ng/dL
• ESR: elevated, median around 60 to 70 mm/hr in published series [5]
• CRP: elevated, consistent with systemic inflammation
• TPO antibodies: negative or weakly positive (distinguishes from Hashimoto's)
• Thyroglobulin: markedly elevated due to follicular destruction
• Complete blood count: mild leukocytosis common; significant leukocytosis warrants evaluation for suppurative thyroiditis

Subacute Thyroiditis vs. Hashimoto's Thyroiditis

These two conditions both cause thyroid dysfunction but share almost no other features. Hashimoto's thyroiditis is a chronic autoimmune disease driven by lymphocytic infiltration and characterized by strongly positive TPO antibodies (typically >100 IU/mL) and thyroid peroxidase antibodies in over 90 percent of patients, as documented in a large cohort study in Thyroid [9]. The gland is painless and often enlarged with a rubbery consistency.

Subacute thyroiditis produces a tender gland, a very high ESR, absent or low TPO antibodies, and a self-resolving course. Hashimoto's, by contrast, causes progressive and usually permanent hypothyroidism in a substantial proportion of patients. The two conditions can occasionally coexist, but that scenario is uncommon.

Subclinical hypothyroidism, defined as TSH above 4.5 mIU/L with normal free T4, appears transiently in the hypothyroid phase of subacute thyroiditis and should not be automatically treated unless the TSH exceeds 10 mIU/L, symptoms are significant, or the patient is pregnant. This mirrors the threshold recommended by the American Association of Clinical Endocrinology for treatment of subclinical hypothyroidism in the general population [10].

Subacute Thyroiditis vs. Graves' Disease

Graves' disease produces hyperthyroidism through a fundamentally different mechanism: thyroid-stimulating immunoglobulins (TSI) bind TSH receptors and chronically overstimulate hormone production. The gland is not inflamed or painful. RAIU is high (typically 35 to 95 percent), which is the opposite of subacute thyroiditis [7].

Clinically, both conditions can present with palpitations, weight loss, and suppressed TSH. The differentiating features are: neck pain (present in subacute thyroiditis, absent in Graves'), ESR (high in subacute thyroiditis, usually normal in Graves'), RAIU (low vs. high), and TSI or TRAb antibodies (positive in over 95 percent of Graves' patients, absent in subacute thyroiditis) [11].

Treatment also diverges sharply. Graves' disease requires antithyroid drugs such as methimazole 10 to 30 mg/day, radioactive iodine ablation, or thyroidectomy. Subacute thyroiditis requires only pain control and phase-appropriate hormonal support. Prescribing an antithyroid drug during the thyrotoxic phase of subacute thyroiditis is inappropriate and ineffective because the elevated hormone is pre-formed, not newly synthesized [1].

Treatment: Pain Control and Phase-Specific Hormonal Management

Pain Management

Pain is the dominant symptom in phase 1. For mild to moderate neck pain, the American Thyroid Association recommends starting with NSAIDs: aspirin 650 mg every six hours or ibuprofen 400 to 600 mg every six to eight hours [1]. If pain is not adequately controlled within 48 to 72 hours, escalate to corticosteroids.

Prednisone 40 mg/day orally produces dramatic pain relief, often within 24 hours. After pain resolves, taper by 10 mg every one to two weeks over four to six weeks to minimize rebound. A 2021 retrospective analysis in Thyroid noted that abrupt discontinuation of corticosteroids is associated with symptomatic relapse in approximately 20 percent of patients, reinforcing the importance of a gradual taper [12].

Beta-blockers, specifically propranolol 10 to 40 mg every six to eight hours or atenolol 25 to 50 mg once daily, can control adrenergic symptoms such as palpitations and tremor during the thyrotoxic phase. They do not alter the disease course but improve quality of life substantially during those first several weeks [1].

Managing the Hypothyroid Phase

Most patients in phase 3 have mild, transient hypothyroidism that does not require levothyroxine. Watchful waiting with repeat TSH in four weeks is the preferred approach when TSH is between 4.5 and 10 mIU/L and symptoms are minimal [6]. Start levothyroxine at 1.6 mcg/kg/day when:

• TSH exceeds 10 mIU/L, or
• Symptoms of hypothyroidism are significantly affecting quality of life, or
• The patient is pregnant or planning conception

Recheck TSH at six to eight weeks after starting levothyroxine. Once the TSH normalizes and the patient has been asymptomatic for three to four months, attempt a slow wean to confirm whether permanent hypothyroidism has developed. The FDA-approved starting dose for levothyroxine in adults with hypothyroidism is 1.6 mcg/kg/day, with adjustments based on serial TSH measurements [13].

Patients Who Should Not Receive Corticosteroids

Corticosteroids carry real risks. Patients with uncontrolled diabetes (HbA1c >9%), active peptic ulcer disease, or significant osteoporosis require individualized risk-benefit discussions before prednisone is initiated. In those patients, an extended NSAID trial with a proton pump inhibitor, or pain management with a non-steroidal alternative, is a reasonable approach while monitoring the clinical course.

Monitoring Schedule and When to Refer

A practical follow-up framework for primary care:

• Week 0 (diagnosis): TSH, free T4, ESR, CRP, TPO antibodies, RAIU or thyroid ultrasound
• Week 4: TSH, free T4, symptom reassessment
• Week 8: TSH, free T4; if TSH remains suppressed, consider endocrinology referral
• Week 12: TSH, free T4; if TSH is elevated and free T4 is low, initiate levothyroxine
• Month 6: TSH; if normal and patient is on levothyroxine, begin taper to confirm recovery

Refer to endocrinology when: RAIU is unavailable and the diagnosis is uncertain; the patient is pregnant; TSH remains suppressed beyond eight weeks (atypical for subacute thyroiditis and raises concern for Graves' disease or toxic adenoma); or permanent hypothyroidism is suspected.

Recurrence and Long-Term Prognosis

Recurrence after a first episode of subacute thyroiditis is uncommon. Published series place the recurrence rate at approximately 2 percent, and recurrent episodes tend to be milder than the initial presentation [14]. Permanent hypothyroidism, the primary long-term risk, occurs in 5 to 15 percent of patients and is more likely in those who experienced a prolonged hypothyroid phase or who have subclinical TPO antibody positivity [6].

Prognosis overall is favorable. A Swedish cohort following 359 patients for a median of 7.5 years found that 89 percent achieved complete, sustained euthyroidism without ongoing medication [14]. Patients with persistent subclinical hypothyroidism after six months should have TSH rechecked annually.

Subacute Thyroiditis During Pregnancy

Pregnancy complicates the picture. Subacute thyroiditis presenting during or immediately after pregnancy requires urgent endocrinology involvement because both untreated thyrotoxicosis and untreated hypothyroidism carry fetal risk. Postpartum thyroiditis, a separate but related condition, shares a similar phase pattern and affects approximately 5 to 10 percent of women in the year after delivery, according to a review in Thyroid [15]. The two conditions can be difficult to distinguish clinically, though postpartum thyroiditis is typically painless and strongly associated with TPO antibody positivity.

The American Thyroid Association's guidelines for thyroid disease in pregnancy specify that TSH should be maintained below 2.5 mIU/L in the first trimester and below 3.0 mIU/L thereafter, making early diagnosis and phase-appropriate treatment especially time-sensitive in pregnant patients [15].